Geistlich appoints Diego Gabathuler as new CEO. As a proven leader, he brings many years of experience in the MedTech industry and will continue to drive the company's expansion strategy in regenerative medicine.

Geistlich Pharma AG has appointed Diego Gabathuler as its new CEO effective December 1, 2023. He succeeds Ralf Halbach, who departed the company in August 2023.

Diego Gabathuler is a 49-year-old Swiss National who brings a broad range of experience from various management positions as well as extensive knowledge in business development and strategic marketing.

Most recently, he was CEO of the dental company Ivoclar. He has expertise in the MedTech sector, excellent leadership qualities, and a proven strategic acumen. His professional career also includes management positions at international digital-tech companies such as Logitech, Activision and Electronic Arts.

Andreas Geistlich, Chairman of the Board of Directors, who held the CEO position on an interim basis: "The Geistlich strategic plan includes further investment in new products, solutions and technologies in order to apply regenerative medicine in helping even more people around the world. We are convinced that Diego Gabathuler's expertise will support us significantly in this mission."

Geistlich wishes Diego a successful start, and we look forward to working with him to further advance the future of regenerative medicine.

About Geistlich Pharma AG (Geistlich)
Geistlich is a global leader dedicated to advancing regenerative medicine. Geistlich has been the world market leader in the field of regenerative dentistry for many years. In addition, Geistlich is committed to providing comprehensive support to clinicians in the field of regenerative medicine through scientific research, innovative developments as well as educational programs. Geistlich is a Swiss family-owned company with tradition since 1851. With 13 subsidiaries and 60 distributors, the company reaches around 90 markets and employs over 800 people.